Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOBEEN H RATHORE

Allopathic & Osteopathic Physicians Pediatrics Pediatric Infectious Diseases

NPI
1245299320
CMS profile
101360
Location
JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$7,023.35

11 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $6,210.00 1
Travel and Lodging $622.27 5
Food and Beverage $191.08 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
SANOFI PASTEUR INC. $7,023.35 11

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOBEEN H RATHORE

NPI 1245299320 · CMS profile ID 101360

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Infectious Diseases

JACKSONVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1245299320?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOBEEN H RATHORE, NPI 1245299320, CMS profile ID 101360. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1245299320?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MOBEEN H RATHORE, NPI 1245299320, CMS profile ID 101360. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1245299320?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MOBEEN H RATHORE, NPI 1245299320, CMS profile ID 101360, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–11 of 11 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1245299320?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

11 matching records · $7,023.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 11 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–11 of 11.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SANOFI PASTEUR INC. $50.0001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916058 CMS
SANOFI PASTEUR INC. $35.0001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916065 CMS
SANOFI PASTEUR INC. $50.0001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916073 CMS
SANOFI PASTEUR INC. $6,210.0001/26/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916081 CMS
SANOFI PASTEUR INC. $14.7001/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916089 CMS
SANOFI PASTEUR INC. $41.3801/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916097 CMS
SANOFI PASTEUR INC. $51.3501/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916105 CMS
SANOFI PASTEUR INC. $48.0001/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916113 CMS
SANOFI PASTEUR INC. $2.0001/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916121 CMS
SANOFI PASTEUR INC. $403.9201/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916041 CMS
SANOFI PASTEUR INC. $117.0001/25/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043916049 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,866.71 2
PY2021 $8,670.00 3
PY2022 $7,102.52 10
PY2023 $7,023.35 11
PY2024 $2,000.00 1
PY2025 $65.02 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $137,102.80 37
PY2024 Recipient $669.58 2
PY2024 Principal investigator $96,258.25 30
PY2023 Principal investigator $434,794.19 88
PY2022 Principal investigator $1,042,249.00 59
PY2021 Principal investigator $243,963.73 16
PY2020 Recipient $649.69 1
PY2020 Principal investigator $11,740.58 12
PY2019 Principal investigator $23,459.64 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $57.56 12/31/2022 Non-covered Recipient Entity
BAPTIST MEDICAL CENTER,WOLFSON CHILDRENS HOSPITAL
A Phase 2 Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozone,Tazobactam MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Subjects with Complicated Intra-Abdominal Infections No dispute reported 06/30/2026 940419457
Principal investigator 1 ModernaTX, Inc. $18,318.56 12/20/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263109
Principal investigator 1 ModernaTX, Inc. $722.80 12/20/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263115
Principal investigator 1 ModernaTX, Inc. $1,521.00 12/20/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263121
Principal investigator 1 ModernaTX, Inc. $290.23 12/13/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263103
Principal investigator 1 ModernaTX, Inc. $3,044.60 12/08/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263097
Principal investigator 1 ModernaTX, Inc. $1,170.00 12/08/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263137
Principal investigator 1 ModernaTX, Inc. $259.28 12/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263085
Principal investigator 1 ModernaTX, Inc. $5,211.70 12/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263091
Principal investigator 1 ModernaTX, Inc. $1,337.05 12/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263081
Principal investigator 1 ModernaTX, Inc. $2,800.00 12/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263127
Principal investigator 1 ModernaTX, Inc. $800.00 12/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263133
Principal investigator 1 ModernaTX, Inc. $13,740.35 11/22/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263029
Principal investigator 1 ModernaTX, Inc. $975.00 11/15/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262977
Principal investigator 1 ModernaTX, Inc. $10,441.28 11/10/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262983
Principal investigator 1 ModernaTX, Inc. $3,705.00 11/10/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262989
Principal investigator 1 ModernaTX, Inc. $3,705.00 11/10/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262995
Principal investigator 1 ModernaTX, Inc. $3,705.00 11/10/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263001
Principal investigator 1 ModernaTX, Inc. $3,130.73 11/10/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963263007
Principal investigator 1 ModernaTX, Inc. $22,808.50 10/27/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262949
Principal investigator 1 ModernaTX, Inc. $8,543.28 10/25/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262937
Principal investigator 1 ModernaTX, Inc. $4,223.70 10/13/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262921
Principal investigator 1 ModernaTX, Inc. $79,633.39 10/11/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262909
Principal investigator 1 ModernaTX, Inc. $4,212.00 10/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262959
Principal investigator 1 ModernaTX, Inc. $5,889.00 10/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262965
Principal investigator 1 ModernaTX, Inc. $103,576.72 10/04/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262903
Principal investigator 1 ModernaTX, Inc. $76,364.75 09/23/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262243
Principal investigator 1 ModernaTX, Inc. $259.35 09/15/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262091
Principal investigator 1 ModernaTX, Inc. $1,600.00 09/09/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262155
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/09/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262163
Principal investigator 1 ModernaTX, Inc. $2,400.00 09/09/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262173
Principal investigator 1 ModernaTX, Inc. $3,900.00 09/02/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262185
Principal investigator 1 ModernaTX, Inc. $1,600.00 09/01/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262149
Principal investigator 1 ModernaTX, Inc. $800.00 08/11/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262121
Principal investigator 1 ModernaTX, Inc. $50,318.84 07/26/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262231
Principal investigator 1 ModernaTX, Inc. $364.33 07/14/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262097
Principal investigator 1 ModernaTX, Inc. $1,648.73 07/14/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262825
Principal investigator 1 ModernaTX, Inc. $28,217.28 07/14/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262835
Principal investigator 1 ModernaTX, Inc. $34,234.20 07/14/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262841
Principal investigator 1 ModernaTX, Inc. $400.00 05/24/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262103
Principal investigator 1 ModernaTX, Inc. $400.00 05/24/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262109
Principal investigator 1 ModernaTX, Inc. $400.00 05/24/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262115
Principal investigator 1 ModernaTX, Inc. $3,260.40 05/24/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262179
Principal investigator 1 ModernaTX, Inc. $69,565.44 05/24/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262237
Principal investigator 1 ModernaTX, Inc. $76,510.72 05/24/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262249
Principal investigator 1 ModernaTX, Inc. $2,400.00 04/12/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262169
Principal investigator 1 ModernaTX, Inc. $901.55 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262125
Principal investigator 1 ModernaTX, Inc. $1,278.23 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262143
Principal investigator 1 ModernaTX, Inc. $16,150.00 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262197
Principal investigator 1 ModernaTX, Inc. $16,329.17 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262203
Principal investigator 1 ModernaTX, Inc. $21,612.50 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262209
Principal investigator 1 ModernaTX, Inc. $22,275.00 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262215
Principal investigator 1 ModernaTX, Inc. $25,694.18 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262221
Principal investigator 1 ModernaTX, Inc. $27,596.08 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262227
Principal investigator 1 ModernaTX, Inc. $117,690.56 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262255
Principal investigator 1 ModernaTX, Inc. $124,655.96 02/17/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262261
Principal investigator 1 ModernaTX, Inc. $1,200.00 01/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262131
Principal investigator 1 ModernaTX, Inc. $5,200.00 01/06/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262191
Principal investigator 1 ModernaTX, Inc. $1,200.00 01/04/2022 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 963262137